Metagen Therapeutics Raises 300 Million Yen In Series B Extension
The raise extends a gut bacteria pipeline into clinical work for ulcerative colitis, gastrointestinal cancer, and Parkinson's disease, and it puts an impact fund behind a stool donation supply chain rather than a conventional drug candidate.
Reporting from 1 source: ASCII.jp.
Metagen Therapeutics, based in Tsuruoka City, Yamagata Prefecture, raised 300,036,750 yen from GLIN Impact Capital in the second close of its Series B extension round in September 2026. The round now totals 490 million yen, and cumulative funding reaches 7.14 billion yen. The funds go to clinical development of the oral FMT drug MGT-006 for ulcerative colitis and to other gut bacteria programs.
The second close adds GLIN Impact Capital as a subscriber through a third-party allotment of new shares. Metagen Therapeutics runs a supply chain that covers gut bacteria donor recruitment and screening, stool collection, and investigational drug manufacturing, based at a stool donation facility in Tsuruoka City, Yamagata Prefecture.
The company is running Phase 1/Phase 2 trials of MGT-006, an oral FMT drug for ulcerative colitis, in Japan and the United States. It also points to clinical research on ulcerative colitis, gastrointestinal cancer, and Parkinson's disease, and to MGT-001, MGT-007, and MGT-008 among the programs the proceeds will support.
Synthesized by Yomimono from the 1 cited source below, including Japanese-language reporting where cited, then editorially reviewed before publishing.